Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

 
• By Joseph Haas, John Davis, Alexandra Shimmings, Jung Won Shin, and Ian Haydock

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

DealWatch_1200x675

More from Deals

More from Business